Status
Conditions
Treatments
About
This trial is being conducted to determine the impact of whole body FDG PET-CT vs. conventional staging in the management of patients presenting with clinical Stage III breast cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting patients with lobular only histology will be entered into a separate single arm prospective study and will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen & pelvis and a bone scan.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Women (or men) with histological evidence of breast cancer for whom potentially curative treatment is planned.
Based on clinical information (physical exam, imaging):
Considered for combined modality therapy (surgical resection, chemotherapy, radiotherapy) of curative intent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
369 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal